Bromocriptine Mesylate
Who holds supplier records for Bromocriptine Mesylate? 4 organisations hold a current record for Bromocriptine Mesylate: an active US FDA Type II Drug Master File or a CEP. A further 5 organisations have only historical (inactive) DMF filings. 2 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: Italy (1), Slovenia (1), Netherlands (1) and Czech Republic (1).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Bromocriptine Mesylate: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/bromocriptine-mesylate
Reading the evidence
- 4 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 3 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (4)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Bromocriptine Mesylate. Country is the organisation's recorded country, not necessarily the manufacturing site.
- CURIA ITALY SRLItalyCEP Company GMP cert on recordActive DMF 6955 · latest filing May 1987
- Lek Pharmaceuticals D.D.Slovenia Company GMP cert on recordActive DMF 6827 · latest filing Feb 1987
- TAPI NL BVNetherlandsActive DMF 14768 · latest filing Mar 2000
- TAPI Czech Industries s.r.oCzech RepublicCEP Company GMP cert on record
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (2)
Certificates of Suitability on the EDQM register for Bromocriptine Mesylate, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| TAPI CZECH INDUSTRIES S.R.O. Opava | CZ | CEP 2006-281 - Rev 04 Bromocriptine mesilate | Mar 2025 | Inspected Oct 2024 Czechia |
| CURIA ITALY S.R.L. Rozzano, Milano | IT | R1-CEP 2000-151 - Rev 07 Bromocriptine mesilate | Aug 2021 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Historical records (5)
Organisations whose Type II DMFs for Bromocriptine Mesylate are no longer active. These show a past filing, not current supply.
Show all 5 historical records
- GALENA ASInactive DMF 11973 · filed May 1996
- CHEMICAL PHARMACEUTICAL RESEARCH INSTITUTE NIHFI LTDInactive DMF 10679 · filed Dec 1993
- LABOCHIMInactive DMF 7088 · filed Jul 1987
- CHEMAPOL LTDInactive DMF 6984 · filed May 1987
- Hungary · Inactive DMF 6737 · filed Dec 1986
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Bromocriptine Mesylate is an ergot derivative medication primarily used in the treatment of hyperprolactinemia, Parkinson's disease, and Type 2 diabetes. It acts as a dopamine D2 receptor agonist to inhibit the secretion of prolactin from the pituitary gland.
Chemical identity
- IUPAC name
- (6aR,9R)-5-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;methanesulfonic acid
- Canonical SMILES
- CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.CS(=O)(=O)O
- InChIKey
- NOJMTMIRQRDZMT-GSPXQYRGSA-N
- Synonyms
- Parlodel API, 2-bromoergocryptine mesylate, bromocriptine mesilate, bromocriptine methanesulfonate, cb-154, cb-154 mesilate, cb-154 mesylate, cycloset, nsc-755915, parlodel
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Ergot Derivative
- Chemical structure
- Ergolines
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Bromocriptine Mesylate?
4 organisations hold an active US FDA Type II Drug Master File or a CEP for Bromocriptine Mesylate: CURIA ITALY SRL (Italy), Lek Pharmaceuticals D.D. (Slovenia), TAPI NL BV (Netherlands) and TAPI Czech Industries s.r.o (Czech Republic). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Bromocriptine Mesylate Drug Master Files are active?
CURIA ITALY SRL (DMF 6955), Lek Pharmaceuticals D.D. (DMF 6827) and TAPI NL BV (DMF 14768). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Bromocriptine Mesylate records mean?
5 organisations have only inactive Type II DMFs for Bromocriptine Mesylate. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does Bromocriptine Mesylate have a European Certificate of Suitability?
Yes. 2 organisations hold a valid CEP for Bromocriptine Mesylate on the EDQM register, including TAPI CZECH INDUSTRIES S.R.O. Opava (CZ) and CURIA ITALY S.R.L. Rozzano, Milano (IT). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
How do I qualify a Bromocriptine Mesylate supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Bromocriptine Mesylate?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.